Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/19539
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
Metadatos
Mostrar el registro completo del ítem
SECURING THE PUBLIC GOOD OF HEALTH RESEARCH AND DEVELOPMENT FOR DEVELOPING COUNTRIES
Autor
Afiliación
University of Oslo. Institute for Health and Society. Department of Health, Management and Health Economics. Oslo, Norway.
Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brasil.
Department of Health and Family Welfare. New Delhi, India.
Ministry of Public Health. Department of Statistics. Beirut, Lebanon.
Philippine Health Insurance Corporation. Office of the Chairman of PhilHealth Board. Manila, Philippines.
University of Cape Town. Groote Schuur Hospital. Cape Town, South Africa.
Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brasil.
Department of Health and Family Welfare. New Delhi, India.
Ministry of Public Health. Department of Statistics. Beirut, Lebanon.
Philippine Health Insurance Corporation. Office of the Chairman of PhilHealth Board. Manila, Philippines.
University of Cape Town. Groote Schuur Hospital. Cape Town, South Africa.
Resumen en ingles
Securing access to medicines and other health technologies in developing countries continues to be among the major challenges for global health. The challenge lies in ensuring that existing health products are delivered at affordable prices and that innovations and discoveries meet the health needs of developing countries. This policy problem calls for both global and national policy instruments. When in 2001 the Commission on Macroeconomics and Health categorized diseases as type I, II and III based on the extent to which they affected countries at different economic levels, it was alienating for many public health professionals.
1
However,
it represented a reality. The classifica
-
tion captured the idea that the existing
system provided inadequate incentives
for the development of health technolo
-
gies designed to address diseases that
primarily affect developing countries
(type II and III diseases).
Compartir